Entries by groupH

groupH’s strategic Market Access practice reports favourable payer views on novel long-acting injectables

groupH’s strategic Market Access practice reports favourable payer views on novel long-acting injectables. The Market Access team here at groupH, with permission from MedinCell, recently published a White Paper; revealing in-depth payers’ views on the prospects of value creation through novel long-acting injectables, the challenges associated with evidence generation, and the potential to translate value […]

2014 … a year in 2 min 14 sec

‘Can I discuss an idea with you perhaps tomorrow? It’s difficult to write this in an e-mail but easier to discuss or brainstorm by phone potentially… are you around?’ Erik had this idea in mind for a different Christmas card this year. ‘Can we show what groupH does through the means of movement and dance? […]

2014 … a year in 2 min 14 sec (Behind-the-scenes commentary)

‘Can I discuss an idea with you perhaps tomorrow? It’s difficult to write this in an e-mail but easier to discuss or brainstorm by phone potentially… are you around?’ Erik had this idea in mind for a different Christmas card this year. ‘Can we show what groupH does through the means of movement and dance? […]

How groupH can assist in developing Market Access strategies

The importance of planning market access strategies at an early stage. There is an ever-increasing influence of payers in treatment decision-making processes. The commercial success of new pharmaceutical agents will therefore be heavily dependent on their market access position. In the past it was the norm to engage with regulators at an early stage of […]

Pharmaceutical forecasting: throwing darts or adding value?

Several clients have brought this review from McKinsey, the global management consultancy, to our attention over the last few weeks.  It’s prompted us to reflect on the forecasting we conduct with our clients and put down our opinions on the value of the forecasting process.  It also gives us the opportunity to listen to your […]

Manage your energy, not your time

Sometimes a novel approach to working effectively comes along that really resonates. For groupH, Tony Schwartz and Catherine McCarthy’s tried and tested approach, published in the Harvard Business Review back in 2007, did just that. They described how organizations are demanding ever-higher performance from their workforces and that staff are trying to comply, by working […]

Keeping abreast of changing dynamics in the Japanese Pharma market

Recent initiatives are changing the dynamics in the Japanese pharmaceutical market.  At one end of the spectrum, a trial process is rewarding innovation by exempting new drugs from biennial price cuts in return for investing in areas of unmet need, whilst other measures are speeding up drug approvals.  At the other end, the need to […]

Will new developments change the treatment paradigm in RA?

A new era of targeted oral therapies? Rheumatoid arthritis (RA) treatment options have expanded from conventional oral therapies like methotrexate, through the era of targeted injectable biologics and into a new dawn of targeted oral treatment. Xeljanz, Pfizer’s first-in-class JAK3 inhibitor (tofacitinib), was launched in the US in 2012 – the first oral therapy approved […]

Fresh approaches to visualising information

Here at groupH, we are always looking for new ways to present information, data and concepts more cleanly and more concisely. We have found the following websites inspiring, and hope you do too: Beautiful: http://www.informationisbeautiful.net/tag/health/ Informative: (The Economist’s daily chart) http://www.economist.com/blogs/graphicdetail Scientific and Statistical: http://www.datavis.ca/gallery/bright-ideas.php Tools: http://www.idea.org/blog/2012/10/25/great-tools-for-data-visualization/